Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 1.00 |
| ▸ | PPARG | P37231 | 15/20 | 1.00 |
| ▸ | RXRA | P19793 | 13/20 | 1.00 |
| ▸ | RXRB | P28702 | 11/20 | 1.00 |
| ▸ | RXRG | P48443 | 10/20 | 1.00 |
| ▸ | PPARD | Q03181 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirinixic Acid SCHEMBL29370056 | 1.00 | PPARA (1.00) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11833234 | 0.90 | PPARA (0.82) | PPARAPPARGRXRARXRBRXRG | |
| Pirinixic Acid SCHEMBL6563348 | 0.89 | PPARA (0.80) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL6563962 | 0.88 | PPARA (0.78) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11483023 | 0.87 | PPARA (0.77) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL6565495 | 0.87 | PPARA (0.77) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11483773 | 0.86 | PPARA (0.76) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11492690 | 0.86 | PPARA (0.76) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11484264 | 0.85 | PPARA (0.74) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11491689 | 0.85 | PPARA (0.74) | PPARAPPARGRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572781-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2025-06-25 | — | — | EP | claimed |
| US-20250009744-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-01-09 | — | — | US | claimed |
| US-20240398789-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2024-12-05 | — | — | US | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2024040132-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2024-02-22 | — | — | WO | claimed |
| EP-4322939-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-02-21 | — | — | EP | claimed |
| US-20230420110-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-12-28 | — | — | US | claimed |
| EP-4247259-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | Indiana University Research and Technology Corporation (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007101005-A2 | COMPOSITIONS AND METHODS FOR EFFECTING CONTROLLED POSTERIOR VITREOUS DETACHMENT | BAUSCH & LOMB INCORPORATED (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070196350-A1 | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment | BAUSCH & LOMB INCORPORATED | 2007-08-23 | — | — | US | claimed |
| EP-1814582-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | Intercept Pharmaceuticals Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060252670-A1 | Method of reducing drug-induced adverse side effects in a patient | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006044391-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005034735-A2 | METHOD FOR ASSESSING THE RISK FOR INSULIN RESISTANT DIABETES AND/OR HEART DISEASE | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| US-20040224995-A1 | Neuroprotective effects of PPARy agonists against cellular oxidative insults | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH | 2004-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224995-A1 | Neuroprotective effects of PPARy agonists against cellular oxidative insults | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885RXRA 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.